Multitude Therapeutics

Company snapshot

Multitude Therapeutics (MTX) is a spinoff company created by Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy. MTX focuses on developing novel antibody-drug conjugates (ADC), CAR-Ts and immuno-oncology antibodies for solid and hematological tumors. MTX’s therapeutic programs are based on novel cancer and immune cell surface targets discovered by

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Multitude Therapeutics. Not investment advice.

• What is Multitude Therapeutics?

  Multitude Therapeutics is a pharma organization headquartered in CN. Primary therapeutic focus areas include Advanced Solid Tumor, Advanced Solid Tumors. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Cli

• Is Multitude Therapeutics publicly traded?

  Multitude Therapeutics appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Multitude Therapeutics develop or market?

  No drug profiles are currently linked to Multitude Therapeutics. Pipeline programs may still list investigational assets.

• What are the latest developments for Multitude Therapeutics?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Multitude Therapeutics focus on?

  Multitude Therapeutics focuses on Advanced Solid Tumor, Advanced Solid Tumors based on our analysis of their pipeline programs and drug development activities.